Tositumomab
Prijeđi na navigaciju
Prijeđi na pretragu
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 192391-48-3 |
| ATC kod | V10XA53 |
| DrugBank | DB00081 |
| ChEMBL[1] | CHEMBL1201604 
|
| Hemijski podaci | |
| Formula | C6416H9874N1688O1987S44 |
| Mol. masa | 143859.7 g/mol |
| Fizički podaci | |
| Tačka topljenja | 61 °C (142 °F) |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 0,8 sati |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravenozno |
Tositumomab je lek za tretman folikularnog limfoma. On je IgG2a anti-CD20 monoklonalno antitelo izvedeno iz imortalizovanića ćelija miša.[2][3]
Reference[uredi | uredi kod]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
